MX2023006599A - Metodos de uso de agentes de interleucina-2. - Google Patents

Metodos de uso de agentes de interleucina-2.

Info

Publication number
MX2023006599A
MX2023006599A MX2023006599A MX2023006599A MX2023006599A MX 2023006599 A MX2023006599 A MX 2023006599A MX 2023006599 A MX2023006599 A MX 2023006599A MX 2023006599 A MX2023006599 A MX 2023006599A MX 2023006599 A MX2023006599 A MX 2023006599A
Authority
MX
Mexico
Prior art keywords
agents
methods
interleukin
variants
treat
Prior art date
Application number
MX2023006599A
Other languages
English (en)
Inventor
Zachary Shriver
Gregory Babcock
Boopathy Ramakrishnan
Scott Moore Carlson
Jesus Borges Thiago De
Leonardo Vidal Riella
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2023006599A publication Critical patent/MX2023006599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan agentes de IL-2 que comprenden variantes de IL-2, así como métodos, composiciones y usos de los mismos; los agentes de IL-2 aquí descritos pueden utilizarse para tratar y/o prevenir diversos trastornos y afecciones.
MX2023006599A 2020-12-04 2021-12-03 Metodos de uso de agentes de interleucina-2. MX2023006599A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121726P 2020-12-04 2020-12-04
US202163283822P 2021-11-29 2021-11-29
PCT/US2021/061883 WO2022120224A1 (en) 2020-12-04 2021-12-03 Methods of using interleukin-2 agents

Publications (1)

Publication Number Publication Date
MX2023006599A true MX2023006599A (es) 2023-06-19

Family

ID=79288050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006599A MX2023006599A (es) 2020-12-04 2021-12-03 Metodos de uso de agentes de interleucina-2.

Country Status (9)

Country Link
US (1) US20220177535A1 (es)
EP (1) EP4255466A1 (es)
JP (1) JP2024502708A (es)
KR (1) KR20230129018A (es)
AU (1) AU2021391924A1 (es)
CA (1) CA3203977A1 (es)
MX (1) MX2023006599A (es)
TW (1) TW202237171A (es)
WO (1) WO2022120224A1 (es)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es) * 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
AU2016246152A1 (en) * 2015-04-10 2017-11-02 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
JP7464389B2 (ja) 2016-08-02 2024-04-09 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CN114450298A (zh) 2019-07-26 2022-05-06 威特拉公司 白介素-2制剂及其用途

Also Published As

Publication number Publication date
AU2021391924A9 (en) 2024-02-08
US20220177535A1 (en) 2022-06-09
EP4255466A1 (en) 2023-10-11
TW202237171A (zh) 2022-10-01
AU2021391924A1 (en) 2023-06-22
JP2024502708A (ja) 2024-01-23
KR20230129018A (ko) 2023-09-05
CA3203977A1 (en) 2022-06-09
WO2022120224A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2022009164A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2022012474A (es) Compuestos y usos de estos.
ZA202207804B (en) Compounds and uses thereof
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
MX2021008364A (es) Amidas de pirrolidina iii sustituidas.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2022009308A (es) Compuestos y usos de estos.
MX2021000759A (es) Derivados de triazolquinoxalina adicionalmente sustituidos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2021000762A (es) Derivados de triazoloquinoxalina sustituida.
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2022009367A (es) Compuestos y usos de estos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2022000811A (es) Inhibidores de enzimas.